Successful Launch of Rezdiffra
Madrigal Pharmaceuticals achieved $103 million in net sales in Q4 2024, marking a 66% quarter-over-quarter growth. For the full year, the company generated $180 million in net sales, despite launching only in April.
Significant Prescriber Engagement
By the fourth quarter, approximately 60% of the top 6,000 target prescribers had prescribed Rezdiffra, up from 40% in the third quarter. Overall, 40% of the total 14,000 target prescribers had prescribed the drug by year-end.
Promising Data for Compensated MASH Cirrhosis
Two-year data from the Phase 3 MAESTRO-NAFLD trial showed a mean 6.7 kPa reduction in liver stiffness among F4c MASH patients, which is associated with a decreased risk of liver-related clinical events.
Strong Financial Position
Madrigal ended 2024 with $931.3 million in cash, cash equivalents, restricted cash, and marketable securities, positioning the company well to support ongoing and planned launches.